Open-Label Trial Designs Do Not Seem to Influence Patient-Reported Outcomes
Source: Cancer Therapy Advisor, January 2023
Patient-reported outcomes (PROs) in oncology trials are similar whether the trials have open-label or blinded designs, according to research published in JNCI Cancer Spectrum.
Researchers found no significant differences in PRO measures between open-label and blinded trials of patients with melanoma or non-small cell lung cancer (NSCLC).
For this study, researchers compared an open-label trial and a blinded trial of melanoma patients, as well as an open-label trial and a blinded trial of NSCLC patients.